Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. notified that its Audit Committee dismissed Crowe LLP as the company's independent registered public accounting firm, effective immediately, and engaged Deloitte to serve as the new independent registered public accounting firm to audit the consolidated financial statements for the year ending December 31, 2025. The engagement with Deloitte was communicated on September 17, 2025 and is subject to Deloitte's standard client acceptance procedures and execution of an engagement letter. The filing references a letter from Crowe LLP dated September 19, 2025, and an Inline XBRL cover page file as exhibits. The disclosure does not state the reasons for the change or provide audit opinions or financial impacts.